On the contrary, IL-4/13 significantly decreased, while IFN-a increased the expression of LEKTI and caspase-14.
LEKTI inhibits FLG degradation processing through suppressing the proteases mentioned above.
Here, we examined the expression of FLG and related serine proteases (KLK5, KLK7, matriptase, and CAP1), cysteine protease caspase-14, and LEKTI by immunohistochemical staining in acute and chronic lesions of AD.
Expression of FLG, LEKTI, caspase14, KLK7, KLK5, matriptase, and CAP1 proteins was evaluated by Western blotting.
As shown in [Figure 1], FLG, LEKTI, and caspase14 expressions were significantly decreased, whereas matriptase, CAP1, KLK5, and KLK7 expressions were increased in acute AD lesions, as compared to normal controls.
As shown in [Figure 4]a, IL-4/13 significantly reduced LEKTI mRNA in both NHK and HaCaT cells.
The protein expression levels of LEKTI by Western blotting analysis were consistent with respective mRNA changes in HC and LC culture conditions, as shown in [Figure 4]b.
LEKTI can globally inhibit FLG degradation processing through suppressing the proteases mentioned above.
LEKTI is expressed in the most differentiated epidermis.
The SPs expression (such as KLK5, 7, matriptase, and CAP1) was higher in acute lesions than chronic lesions, while caspase14, LEKTI expression was lower than in chronic lesions.